FIRST-LINE CHEMOTHERAPY OUTCOMES IN A PATIENT WITH RELAPSED METASTATIC NON-SMALL CELL LUNG CANCER HARBORING AN EGFR EXON 20 INSERTION MUTATION
.
Abstract
Introduction: Non-small cell lung cancer (NSCLC) with exon 20 insertion mutations accounts for 4-10% of all NSCLC patients with EGFR mutations. The primary treatment for NSCLC patients with recurrent metastatic EGFR exon 20 insertion mutations remains platinum-based doublet chemotherapy. However, there are very few studies in Vietnam evaluating the effectiveness of this treatment. Therefore, this study was conducted to evaluate the effectiveness of this therapy in the mentioned patient group.
Subjects and Methods: This is a retrospective cross-sectional descriptive study on 36 NSCLC patients with recurrent metastatic EGFR exon 20 insertion mutations treated with platinum-based doublet chemotherapy from January 2019 to June 2024 at Vietnam National Cancer Hospital to evaluate treatment outcomes and adverse effects of the regimen in this patient group.
Results: The response rate of the regimen was 25%, and the disease control rate was 66.7%. The median progression-free survival (PFS) was 7.0 months. The median overall survival (OS) was 17.6 months. The majority of patients experienced at least one adverse effect, accounting for 80.6%. The most common adverse effects were neutropenia (in 58% of patients), peripheral neuropathy (44%), anemia (48%), and nausea (42%). The most common grade 3 or higher adverse effects were neutropenia (25%), thrombocytopenia (6%) and anemia (8%). Dose reductions and drug discontinuations due to adverse effects were reported in 17% and 8% of patients, respectively.
Conclusion: First-line treatment with platinum-based doublet chemotherapy for recurrent/metastatic NSCLC patients with exon 20 insertion mutations is an effective treatment method with manageable toxicity.
.
Keywords
Non-small cell lung cancer; EGFR exon 20 insertion; platinum-based doublet chemotherapy.
- Beau-Faller M, Prim N, Ruppert AM, et al. Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. Ann Oncol. 2014;25(1):126-131. doi:10.1093/annonc/mdt418
- Yang JCH, Sequist LV, Geater SL, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015;16(7):830-838. doi:10.1016/S1470-2045(15)00026-1
- van Veggel B, Madeira R Santos JFV, Hashemi SMS, et al. Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer. Lung Cancer. 2020;141:9-13. doi:10.1016/j.lungcan.2019.12.013
- Negrao MV, Reuben A, Robichaux JP, et al. Association of EGFR and HER-2 exon 20 mutations with distinct patterns of response to immune checkpoint blockade in non-small cell lung cancer. JCO. 2018;36(15_suppl):9052-9052. doi:10.1200/JCO.2018.36.15_suppl.9052
- Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions | NEJM. Accessed November 24, 2023. https://www.nejm.org/doi/full/10.1056/NEJMoa2306441
- Morita C, Yoshida T, Shirasawa M, et al. Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions. Sci Rep. 2021;11:18762. doi:10.1038/s41598-021-98275-3
- Shah MP, Aredo JV, Padda SK, et al. EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy. Clin Lung Cancer. 2022;23(2):e148-e153. doi:10.1016/j.cllc.2021.07.001
- Yang G, Li J, Xu H, et al. EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study. Lung Cancer. 2020;145:186-194. doi:10.1016/j.lungcan.2020.03.014
- Xu CW, Wang WX, Wang D, et al. Pemetrexed-based chemotherapy for non-small-cell lung cancer patients with EGFR exon 20 insertion mutation: a multicenter study. Transl Lung Cancer Res. 2020;9(5):1853-1861. doi:10.21037/tlcr-20-382
- Wu JY, Yu CJ, Shih JY. Effectiveness of Treatments for Advanced Non-Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations. Clin Lung Cancer. 2019;20(6):e620-e630. doi:10.1016/j.cllc.2019.06.018
